Radretumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Radretumab
Monoclonal antibody
Type Whole antibody
Source Human
Target fibronectin
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
 NYesY (what is this?)  (verify)

Radretumab is an antineoplastic. Philogen, a pharmaceutical company specializing in antibody-drug conjugates, is developing it as a conjugate of Iodine-131 to an antibody which binds to fibronectin extra domain-B for treatment of Hodgkin lymphoma.[1][2]

References[edit]

  1. ^ http://www.philogen.com/en/products/pipeline/radretumab-l19-131i_13.html
  2. ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).